A Phase 2 Randomized, Double-Blind, Placebo-Controlled
Study to Evaluate the Safety, Tolerability, and
Pharmacodynamic Effects of GLY-200 in Type 2 Diabetic
Patients
Study Number: GLY-200-02 
Sponsor: Glyscend, Inc.
Version Number: Amendment 02 Version 01 
Date: 06 October 2022 
Supersedes:
The information contained in this document is the property of Glyscend, Inc. and may not be 
reproduced, published or disclosed to others without written authorization from Glyscend, Inc. 
The information in this document contains trade secrets and commercial information that are 
privileged or confidential and may not be disclosed unless such disclosure is required by 
[CONTACT_784]. In any event, pers ons to whom the information is disclosed must 
be informed that the information is privileged or  confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will appl y equally to all future information supplied to 
you, which is indicated as privileged or confidential.
Amendment 01 Version 01 Dated: 19 July 2022 
Version 1.0 Dated: 02 June 2022
Protocol GLY-200-02 AM02V01
06 October 2022
Confidential        2
6.3 M EASURES TO MINIMIZE BIAS:RANDOMIZATION AND BLINDING .................................29
6.4 S TUDY INTERVENTION COMPLIANCE ...........................................................................29
6.5 D OSE MODIFICATION /ADJUSTMENTS /DELAYS .............................................................29
6.6 C ONTINUED ACCESS TO STUDY INTERVENTION AFTER THE END OF THE STUDY ...........29
6.7 T REATMENT OF OVERDOSE .........................................................................................29
6.8 C ONCOMITANT THERAPY ............................................................................................30
Prohibited Medications, Treatments, and Procedures .............................................30
Rescue Medicine....................................................................................................31
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ...............................................................................31
7.1 D ISCONTINUATION OF STUDY INTERVENTION ..............................................................31
7.2 P ARTICIPANT DISCONTINUATION /WITHDRAWAL FROM THE STUDY ..............................31
Reasons for Discontinuation/Withdrawal ...............................................................31
Handling of Participant Discontinuation/Withdrawal .............................................[ADDRESS_996911] ...................................................................................35
8.3 A DVERSE EVENTS ,SERIOUS ADVERSE EVENTS ,AND OTHER SAFETY REPORTING ........36
Time Period and Frequency for Coll ecting AE and SAE Information.....................36
Method of Detecti ng AEs and SAEs ...................................................................... 36
Follow-up of AEs and SAEs ..................................................................................36
Regulatory Reporting Requirements for SAEs .......................................................37
Pregnancy..............................................................................................................37
Disease-related Events and/or Disease-re lated Outcomes not Qualifying as AEs or 
SAEs ..............................................................................................................................[ADDRESS_996912].........................................................................37
8.4 E XPLORATORY PHARMACODYNAMICS AND PHARMACOKINETICS .................................37
Continuous Glucos e Monito ring............................................................................ 38
9. STATISTICAL CONSIDERATIONS............................................................................38
Protocol GLY-200-02 AM02V01
06 October 2022
Confidential        3
9.1 S TATISTICAL HYPOTHESES ..........................................................................................38
9.2 S AMPLE SIZE DETERMINATION ...................................................................................38
9.3 A NALYSIS SETS ...........................................................................................................38
9.4 S TATISTICAL ANALYSES .............................................................................................39
General Considerations..........................................................................................39
Analysis of Primary Safety and Tolerability  Endpoin ts .......................................... 39
Analysis of Secondary and Explor atory Pharmacodyna mic Endpoi nts...................39
Baseline Descriptive Statistics ...............................................................................39
9.5 I NTERIM ANALYSES ....................................................................................................40
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS .41
10.1 A PPENDIX 1: R EGULATORY ,ETHICAL ,AND STUDY OVERSIGHT CONSIDERATIONS ........41
Regulatory and Ethical Considerations...................................................................41
Informed Consent Process......................................................................................41
Data Protection ......................................................................................................42
Committees Stru cture.............................................................................................42
Safety Oversight ....................................................................................................42
Dissemination of Clinical Study Data.....................................................................42
Data Quality Assurance .........................................................................................42
Source Documents.................................................................................................43
Study Records Re tentio n........................................................................................43
Quality Assurance and Quality C ontrol..................................................................44
Protocol Deviations................................................................................................44
Premature Termination or Study Suspension ..........................................................44
Publication Policy..................................................................................................44
Future Use of Stored Specimens and Data..............................................................45
10.2 A PPENDIX 2: AE S AND SAE S:DEFINITIONS AND PROCEDURES FOR RECORDING ,
EVALUATING ,FOLLOW -UP,AND REPORTING ...........................................................................46
Definition of AE ....................................................................................................46
Definition of SAE..................................................................................................47
Definition of Unanticipated Problems (UP)............................................................48
Recording and Follow-Up of AE and/or SAE.........................................................48
Reporting of SAEs.................................................................................................49
Reporting of UPs ...................................................................................................50
10.3 A PPENDIX 3: C ONTRACEPTIVE AND BARRIER GUIDANCE .............................................51
10.4 A PPENDIX 4: C LINICAL LABORATORY ASSESSMENTS ...................................................52
10.5 A PPENDIX 5: A BBREVIATIONS .....................................................................................54
11. LITERATURE REFERENCES......................................................................................57
12. AMENDMENTS..............................................................................................................58
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              6 
Inclusion/ 
Exclusion  
Criteria:   
  Criteria for inclusion:   
1. Patients diagnosed with type 2 diabetes: 
a. treated with a stable dose of metformin ¬ï750 mg/day for at least 3 
months prior to screening 
b. willing to come off current metformin treatment during washout 
and treatment period 
c. HbA1c ¬ï 6.0 and ¬î 8.5% at screening 
d. completed at least 12 days of me tformin washout without meeting 
rescue criteria prior to dosing  
2. 0DOH RU IHPDOH¬ï 30 DQG¬î  \HDUV ROGDW WKHWLPH RI VFUHHQLQJ  
3. BMI ¬ï 18 and ¬î [ADDRESS_996913] dose of 
study medication (i.e., one sperm cycle) 
9. Female subjects must comply with contraception requirements as 
described in Appendix [ADDRESS_996914] one 
of the following criteria: 
a. Achieved postmenopausal status, defined as: cessation of regular 
menses for at least 12 consecutive months with no alternative 
pathological or physiological cause ; and have a serum follicular 
stimulating hormone (FSH) level with in the laboratory‚Äôs reference 
range for postmenopausal women 
b. Have undergone a documented hys terectomy and/or bilateral 
oophorectomy 
c. Have medically confirmed ovarian failure 
All other female subjects (includi ng women with tubal ligations and 
women who do NOT have a documen ted hysterectomy, bilateral 
oophorectomy and/or ovarian failure) will be considered to be of childbearing potential.  
PLEAS E
 NOTE : ORAL CONTRACEPTION IS NOT ALLOWED  (and is 
exclusionary) IN THIS STUDY AS THE STUDY DRUG (GLY-200) MAY REDUCE THE EFFECTIVENESS OF ORAL CONTRACEPTION DUE TO 
POTENTIAL DISRUPTION ON GI ABSORPTION. 
10. Fully vaccinated against COVID-[ADDRESS_996915] 14 days prior to dosing 
 
Criteria for exclusion:   
1. Women who are pregnant (as confirmed by a serum or urine human 
chorionic gonadotrophin [hCG] test) or lactating 
2. Women of childbearing potential who are using oral contraception  
3. Vegetarian or vegan 
4. Treated with any prescription medication for the treatment of type [ADDRESS_996916] 3 months prior to 
screening 
5. Use of any drug treatment that affects gastric pH (prescription or over-the 
counter), such as H2-receptor antagonists and proton pump inhibitors for 
3 months prior to screening (e.g., famotidine, ranitidine, esomeprazole, dexlansoprazole, omeprazole, pantoprazole)  
6. Use of any drug treatment that aff ects gastrointestinal motility including 
but not limited to cholinergic agonist s and antagonists, prokinetic agents, 
opi[INVESTIGATOR_40500], antidiarrheals, and antibiotics in the last 3 months prior to screening (e.g., cevimeline, pi[INVESTIGATOR_1227], loperamide, 
erythromycin, metoclopramide, domperidone, cisapride, mosapride, 
sincalide) 
7. Any chronic condition that requires oral drug treatment that would violate 
concomitant medication use restrictions described in Section 6.8 (i.e., all 
orally administered concomitant medications must be administered at 
least 2 hours before and 4 hours after GLY-200 dosing), TID (three times 
a day) drugs, or drugs with very narrow therapeutic windows (e.g., 
warfarin) 
8. Fasting blood glucose > 190 mg/dL at screening 
9. Diagnosis or treatment of any clin ically symptomatic biochemical or 
structural abnormality of the GI tract or active disease within 12 months prior to screening; including but not limited to inflammatory bowel 
disease (IBD), irritable bowel syndrome (IBS), gastroesophageal reflux 
disease (GERD), GI cancer, diverticulitis, duodenal ulcer, erosive 
esophagitis, gastric ulcer, pancreatitis , symptomatic gallbladder disease, 
ileus, intestinal/pyloric stenosis/obs truction, fistula, malabsorption, 
esophageal anatomic abnormalities, or other severe GI disease, particularly those that may impact digestion, nutrient absorption, 
intestinal motility, and/or gastric emptying 
10. History of any previous abdominal or intestinal surgery including 
endoscopic, open or laparoscopic thoraci c or abdominal surgery, surgical 
resection of the stomach, small or large intestine (excluding appendectomy, cholecystectomy, or res ection of benign polyps), or of any 
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              8 
other risk of abdominal adhesi ons or obstruction. Appendectomy ¬ï 
months prior to screening is allowed. 
11. Clinically significant symptoms (as determined by [CONTACT_737]) of 
nausea, vomiting, bloating, diarrhea, flatulence, constipation, or 
abdominal pain in the last 30 days prior to screening 
12. Use of systemic corticosteroids by [CONTACT_68058], intravenous, or intramuscular 
route; or potent, inhaled, or intra pulmonary steroids known to have a high 
rate of systemic absorption within [ADDRESS_996917] study particip ation and/or pers onal well-being, 
including but not limited to the following conditions: 
a. Uncontrolled hypertension 
b. Uncontrolled hyperlipi[INVESTIGATOR_17939] 
c. Hepatic disease 
d. Renal disease (eGFR value of <60 mL/min/1.73 m2) based on the 
Modification of Diet in Renal Disease equation. 
e. Endocrine disorder other than diabetes 
f. Cardiovascular event in the last 12 months 
g. Central nervous system diseases 
h. Organ transplantation 
i. Chronic or acute infection 
j. Orthostatic hypotension, fainting spells, or blackouts 
14. Any evidence of or treatment of malignancy (other than localized basal 
cell, squamous cell skin cancer, non-aggressive prostate cancer, or cancer 
in situ that has been resected) within the previous year 
15. Clinically significant electrocardiogram (ECG) abnormalities or vital sign 
abnormalities as determined by [CONTACT_737] 
16. Clinical laboratory test (clinical chemistry, hematology, coagulation 
parameters, or urinalysis) abnormality, other than that related to T2D, 
judged by [CONTACT_729898] 
17. Alanine aminotransferase or aspartate aminotransferase result >2.5 √ó upper limit of normal (ULN) or a total bilirubin result >1.5 √ó ULN 
18. Physical, psychological, or historical finding that, in the Investigator‚Äôs 
opi[INVESTIGATOR_1649], would make the subject unsuitable for the study 
19. Severe infections, injuries, or major surgeries (as determined by [CONTACT_3786]) within [ADDRESS_996918] dose of study drug 
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              9 
21. History of bleeding associated with procedures (e.g., endoscopy or 
phlebotomy) or with use of medications (e.g., nonsteroidal anti-
inflammatory drugs [NSAIDs] or aspi[INVESTIGATOR_248]) within [ADDRESS_996919] for human immunodeficiency virus (HIV), hepatitis B 
surface antigen (HBsAg), or hepatitis C antibodies (HCV) 
23. History of severe allergy to any drug, food, toxin, or other exposure  
24. History of heavy alcohol use within 1 year prior to screening, as defined 
by:  
a. Exceeding [ADDRESS_996920] inks per week for women; one 
standard drink=10 grams of alc ohol (equivalent to 12.5 mL of 
pure alcohol, 285 mL of full-strength beer, 375 mL of mid-
strength beer, 425 mL of low-strength beer, 100 mL of wine, or 30 mL of 40% alcohol spi[INVESTIGATOR_2120]). 
25. History of illicit or prescription drug abuse or addiction within 1 year of 
screening, or positive urine drug scr een at screening and Day -1. The 
urine drug screen may be repeated at the discretion of the Investigator and the reason for repeat needs to be documented clearly (e.g., suspi[INVESTIGATOR_729889]). 
26. Participation in a clinical trial involving the administration of an 
investigational or marketed drug or de vice within [ADDRESS_996921] administration or 
donation or loss of blood (excluding volume drawn at screening) of [ADDRESS_996922] from completing all study 
procedures and complying with study restrictions.  
29. Any other conditions (e.g., not suitable for venous access) or laboratory abnormality that may increase the risk associated with study participation 
or study drug administration or interfere with the interpretation of study 
results and, at the discretion of the investigator, makes the subject 
inappropriate for entry into this study 
Study Assessments: Safety and Tolerability: 
‚Ä¢ Medical history, including evaluation of any on-study AEs and 
concomitant medication use 
‚Ä¢ Height and weight 
‚Ä¢ Physical examination 
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              10 
‚Ä¢ Vital signs (supi[INVESTIGATOR_729890], heart rate, 
respi[INVESTIGATOR_697], body temperature)  
‚Ä¢ 12-lead ECGs 
‚Ä¢ Analysis of laboratory safety markers (including hematology, chemistry, 
coagulation, and urinalysis) 
Exploratory Pharmacodynamics: 
Blood (serum and plasma), stool/fecal samples, and urine samples will be 
collected for analysis and identification of GLY-200-induced PD marker 
changes. 
Statistical 
Considerations:   Overview: 
In general, clinical data will be summarized for each dose group using 
descriptive statistics. 
Safety and Tolerability: 
The primary analysis will assess the safety and tolerability of GLY-[ADDRESS_996923] one dose of study drug 
will be included in the Safety popula tion. The safety endpoint includes 
evaluation of AEs, clinical laboratory assessments, vital signs, 12-lead ECGs, 
and the use of concomitant medications. 
Safety data will be aggregated and ta bulated based on the safety dataset for 
each treatment including but not limited to: 
‚Ä¢ Analysis of withdrawal or suspension of medication due to AEs 
‚Ä¢ Incidence and severity of AEs 
‚Ä¢ Analysis of the correlation between AEs and study drug 
‚Ä¢ Analysis of AE outcome 
‚Ä¢ Analysis of SAEs 
‚Ä¢ Descriptive statistical summary of laboratory tests, vital signs, and ECG data 
‚Ä¢ Incidence of abnormal laboratory results. 
Exploratory Pharmacodynamics: 
PD marker parameters will be summarized using descriptive statistics and 
graphs (mean ¬± SEM) for each treatment at each timepoint.    
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              14 
Abbreviations: BP = blood pressure; CGM = continuous glucose monitor; ECG = electrocardiogram; EOS = End of Study;  ET = Early Termination; FSH = 
follicular stimulating hormone; HR = heart rate; MMTT = mixed meal tolerance test; PD = pharmacodynamic(s); PK = pharmacokinetic(s); RR = respi[INVESTIGATOR_862]; Temp = body temperature; VAS = visual analog scale. 
Note: Prescreening laboratory values can be used to determine subject eligibility if they were collected within the screening w indow.  
Footnotes:  
1. Subjects are required to fast for at least 8 hours prior to every morning assessment. ‚ÄúPre-dose‚Äù and ‚Äúpost-dose‚Äù refer to the f irst dose of the day. 
2. At the Day -[ADDRESS_996924] subjects to begin the metformin washout.  
3. Eligibility to be confirmed prior to dose administration on Day 1. 
4. BMI to be calculated using the height value recorded at screening. 
5. Full physical examination to include, at a minimum, assessment of the following: assessment of the following systems: HEENT, Mouth/Dental (if required), 
Neck (incl Thyroid & Nodes), Cardiovascular, Respi[INVESTIGATOR_696], Gastrointestinal, Renal, Neurological, Musculoskeletal, Skin, Other 
6. Abdominal physical examination to include palpation, auscultation (noting presence and frequency of bowel sounds), percussion (looking for signs of peritonitis or localized tenderness). Abdominal examinations are to be conducted at indicated study visits prior to dosing, if applicable. 
7. Symptom directed physical examination will include volunteer elicited examinations only.  
8. Patients should be resting in a supi[INVESTIGATOR_21683] [ADDRESS_996925] dose ECGs will be single re adings. In case of evident bad 
quality (e.g., muscle tremor) of the tracing, the ECG will be repeated. ECGs will be taken after at least [ADDRESS_996926] refrain from food for a minimum of 2 hours prior to and a minimum of 1 hour following each administration of GLY-200 or placebo. At study visits where MMTT will be performed, dosing should occur 1 hour prior to the meal challenge (refer to MMTT Test Schedule in Section  1.3.1). 
15. Subjects will be provided collection containers and will be instructed to collect all bowel movements, if possible, within 24 hours of their Day -1 and Day 21 
(EOS) or ET visits. All bowel movements should also be collected at the site, if possible, anytime between check-in on Day -2 a nd Day 1 pre-dose. During 
the inpatient period starting on Day 10 until check-out on Day 14, all bowel movements should be collected. Additional samples are to be collected at the 
Day 21 (EOS) or ET visits if possible. Approximate weights of fecal collections should be recorded by [CONTACT_6624]. Refer to the Laboratory Manual for 
additional details.  
16. Refer to the MMTT Test Schedule in Section  1.3.1  for blood sample collection timepoints on MMTT days.  
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              15 
17. Urine is to be collected over 24 hours for exploratory PK/PD analysis (boron, etc.) from Day -[ADDRESS_996927] from Day 14 to Day 17 and for the 24 
hours prior to their Day 21 (EOS) or ET visit. All samples collected by [CONTACT_729899] 21 ( EOS) or ET visit.      
18. Recording of water and fluids in and output (urine volume out) over [ADDRESS_996928] pre-dose (or ~60 minutes before the meals on Day -1), pre-meal,  immediately post-meal, 
and 30, 60, 90, 120, 150, 180, 210, and [ADDRESS_996929]-meal on the study days indicated. VAS assessments may be performed wit hin a ¬± 10-minute 
window. 
20. CGM automatic applicator will placed/replaced at indicated study visits for continuous measuring throughout the study; for the Day -1 visit, the CGM can be 
placed on Day -2 (check-in). The CGM is to be removed on Day [ADDRESS_996930] common reported AEs were: 
‚Ä¢N a u s e a
‚Ä¢ Decreased appetite
‚Ä¢ Vomiting
‚Ä¢ Abdominal distension
‚Ä¢ Flatulence
‚Ä¢ Diarrhea
‚Ä¢ Constipation
‚Ä¢ Headache
‚Ä¢ Abdominal discomfort
‚Ä¢ Eructation
‚Ä¢ Dry mouth
‚Ä¢ Abdominal pain upper
‚Ä¢ Dyspepsia
Allergic Reactions
As with any drug, there is the chance of an allergic reaction that may include difficulty breathing, 
rash, flushing, weakness, lightheadedness, dizziness, and swelling. 
Blood Sampling
There is some risk of pain or local bruising and infection at the site where blood is drawn for 
laboratory tests. There is also a small risk of a fainting epi[INVESTIGATOR_1865], which can occur as a reaction to 
giving blood.
The total amount of blood that will be collected over the course of screening and the 21-day 
study is ¬î[ADDRESS_996931]‚Äôs skin on their arms, legs, and chest. The areas where the electrodes will be placed  will be cleaned; some areas may need to be 
shaved. Some skin irritation can occur where the electrodes are placed.
KNOWN POTENTIAL BENEFITS 
Information from this study may help Investig ators and the Sponsor learn more about GLY-200
and its ability to improve the management of uncontrolled glycemia and increased weight in 
patients with T2D. This information ma y help other subjects in future studies.
OVERALL BENEFIT: RISK CONCLUSION
The results of Glyscend‚Äôs preclinical study program strongly supports the conclusion that GLY-
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              24 
11. Clinically significant symptoms (as determin ed by [CONTACT_737]) of nausea, vomiting, 
bloating, diarrhea, flatulence, constipation, or abdominal pain in the last 30 days prior to 
screening 
12. Use of systemic corticosteroids by [CONTACT_68058], intravenous, or intramuscular route; or potent, 
inhaled, or intrapulmonary steroids known to ha ve a high rate of systemic absorption within 
[ADDRESS_996932] study participation a nd/or personal well-being, including but not limited to the 
following conditions: 
a. Uncontrolled hypertension 
b. Uncontrolled hyperlipi[INVESTIGATOR_17939] 
c. Hepatic disease 
d. Renal disease (eGFR value of <60 mL/min/1.73 m2) based on the Modification of 
Diet in Renal Disease equation. 
e. Endocrine disorder other than diabetes 
f. Cardiovascular event in the last 12 months 
g. Central nervous system diseases 
h. Organ transplantation 
i. Chronic or acute infection 
j. Orthostatic hypotension, fainting spells, or blackouts 
14. Any evidence of or treatment of malignancy (oth er than localized basal cell, squamous cell 
skin cancer, non-aggressive prostate cancer, or cancer in situ that has been resected) within 
the previous year 
15. Clinically significant electrocardiogram (ECG ) abnormalities or vita l sign abnormalities as 
determined by [CONTACT_737] 
16. Clinical laboratory test (clinical chemistr y, hematology, coagul ation parameters, or 
urinalysis) abnormality, other than that related to T2D, judged by [CONTACT_313417] 
17. Alanine aminotransferase or aspartate aminotransferase result >2.5 √ó upper limit of normal 
(ULN) or a total bilirubin result >1.5 √ó ULN 
18. Physical, psychological, or histor ical finding that, in the Investigator‚Äôs opi[INVESTIGATOR_1649], would make 
the subject unsuitable for the study 
19. Severe infections, injuries, or major surgerie s (as determined by [CONTACT_737]) within [ADDRESS_996933] dose of study drug 
21. History of bleeding associated with procedures  (e.g., endoscopy or phlebotomy) or with use 
of medications (e.g., nonsteroidal anti-inflamma tory drugs [NSAIDs] or aspi[INVESTIGATOR_248]) within [ADDRESS_996934] for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), 
or hepatitis C antibodies (HCV) 
Protocol GLY-200-02 AM02V01
06 October 2022
Confidential        33
MEDICAL HISTORY
A medical history will be obtained and will include demographic data (e.g., age, race/ethnicity). 
In addition, medical information will also be recorded, including a detailed oncologic history 
with specifics of previous cancer treatments, other medical and surgical history, medication 
history and drug allergies and any other medical conditions and disease states that, in the opi[INVESTIGATOR_18959], are relevant to the subject‚Äôs study participation.
HEIGHT AND WEIGHT
Body height and weight will be measured, and bod y mass index (BMI) will be calculated using 
the height recorded at screen ing. Height should be measured on a wall-mounted stadiometer. 
Weight should be measured in light -weight clothing, without shoes.
PHYSICAL EXAMINATION 
A complete physical examination w ill be performed at Screening and at the EOS or ET visit. The 
complete physical examination will include, at a minimum, assessment of the following systems: 
HEENT, Mouth/Dental (if required), Neck (including Thyroid & Nodes), Cardiovascular, 
Respi[INVESTIGATOR_696], Gastrointestinal, Renal, Neurol ogical, Musculoskeletal, Skin, Other. All other 
scheduled examinations will be symptom-directed.
All physical examinations are to be conduc ted by a medically qualified Investigator.
ABDOMINAL EXAMINATION
Abdominal examinations are to include at a minimum palpation, auscultation (noting presence 
and frequency of bowel sounds), and percussion (l ooking for signs of peritonitis or localized 
tenderness). Abdominal examinati ons are to be conducted at the study visits indicated in the SoA 
prior to dosing.
Besides local gastrointestinal tolerability effects, such as nausea, vomiting, diarrhea, and 
constipation, there is a theoretical risk of small or large bowel obstruction. To mitigate this risk, 
particular attention will be  applied for abdominal examination, w ith particular interest in signs of 
obstruction (reduced bowel sounds, decreased stool, bilious vomiting, and abdominal discomfort 
and distension). If an obstruction is suspected, the subject will be transferred to a medical facility 
and an abdominal X-ray obtained as well as  other imaging that may be appropriate.
VITAL SIGNS
Vital signs will be measured by a qualified staff member. Vital signs assessments will include 
systolic and diastolic blood pressure, heart rate , respi[INVESTIGATOR_697], and body temperature. Patients 
should be resting in a supi[INVESTIGATOR_21683] 5 minutes prior to and during vital signs 
measurements. 
ELECTROCARDIOGRAMS
Twelve-lead ECGs will be assessed (including but not limited to the measurements of ventricular 
Protocol GLY-200-02 AM02V01 
06 October 2022 
Confidential              34 
heart rate (HR), PR interval, respi[INVESTIGATOR_697] ( RR), QRS duration, QT interval and QT interval 
corrected by [CONTACT_469414]‚Äôs formula [QTcF]). Screening and prior to first dose, triplicate 12-lead 
ECGs each separated by [CONTACT_2669] 1 minute will be taken to establish eligibility at baseline. The 
average value for the triplicate will be utilized for assessing QT interval corrected using 
Fridericia‚Äôs formula (QTcF) exclusion criteria. All other post-first dose ECGs will be single readings. However, if any of the ECG measurements is out of normal range, it will be repeated in 
triplicate (separated by [CONTACT_2669] 1 minute).
ECG normal ranges are as follows:
‚Ä¢ PR interval: 120 msec ‚Äì 220 msec (inclusive);
‚Ä¢ QRS duration: < 120 msec;
‚Ä¢47F) ¬î PVHF PDOHV 47F) ¬î PVHFI emales);
‚Ä¢ HR 45-100 beats/min (inclusive)
If the ‚Äúre-check‚Äù triplicate‚Äôs average is still above these parameters, the PI [INVESTIGATOR_729891] a 
determination on further action. The same model of ECG machine should be used for Screening, 
pre-dose and post-dose readings for all patients. ECGs will be taken after at least [ADDRESS_996935] 8 hours prior to clinical laboratory blood sample 
collection. Samples for local clinical laboratory analysis will be collected by a qualified staff 
member. All safety laboratory assessments will be assessed by a certified local laboratory, using the relevant laboratory‚Äôs internal and standard normal range values.
At a minimum, the following tests will be conducted:
‚Ä¢Hematology: hemoglobin, hematocrit, red blood cell indices, thrombocyte count 
(platelets), reticulocyte c ount, white blood cell count with differential (including 
neutrophils, eosinophils, basophils, lymphocytes and monocytes). 
‚Ä¢Coagulation: international normalized ratio, prothrombin time and activated partial 
thromboplastin time. 
‚Ä¢Chemistry: sodium, potassium, magnesium, chlo ride, bicarbonate, phosphate, calcium, 
amylase, lipase, uric acid, albumin, globulin s, protein, lactate dehydrogenase, creatine 
kinase, creatinine (estimated glomerular filtration rate), blood urea nitrogen, alkaline 
phosphatase, ALT, AST, GGT, total bilirubi n, conjugated and unc onjugated bilirubin, 
total cholesterol, high-density lipoproteins, low-density lipoproteins, triglycerides, glucose. Vitamin and mineral pane ls will be evaluated per the SoA.
‚Ä¢Urinalysis: pH, specific gravity, protein, glucose,  ketones, bilirubin, blood, nitrites, 
urobilinogen, leukocyte esterase. Urine sed iment microscopy will be  conducted in the 
Protocol GLY-200-[ADDRESS_996936]‚Äôs screening clinical 
laboratory test results prior to first dose. The subject must not be treated on Day [ADDRESS_996937].
OTHER LABORATORY TESTS
‚Ä¢ Serology: HIV, HBsAg, HCV antibodies 
‚Ä¢ Follicle-stimulating hormone (FSH) and estrad iol levels (for post-menopausal females only)
‚Ä¢ Drugs of abuse screen: The urine screen will include methamphetamines, opi[INVESTIGATOR_858], cocaine, 
phencyclidine, benzodiazepi[INVESTIGATOR_1651], barb iturates, methadone, amphetamines. 
FLUID BALANCE
Urine samples will be taken for volume over a 24-hour period and compared with intake of fluids 
to provide the fluid balance. 
DOCUMENTATION OF FOOD INTAKE
During the inpatient period, food intake (date, time, and quantity [% consumed based on visual 
estimation]) will be documented daily.
FOOD INTAKE AND APPETITE ASSESSMENTS
Food intake and appetite assessme nts will be performed at breakfast and dinner on Days -1, 1, 
and 13 to assess changes in food intake, kcals, and macronutrients based on food weight 
consumed and nutrient analysis.
For appetite assessments on these days, subjects will complete appetite visual analog scale 
(VAS) questionnaires.
MIXED MEAL TOLERANCE TEST
The MMTT is performed in the morning. Subjects should fast at least 8 hours prior to the 
MMTT. The mixed meal used in this protocol is Ensure Plus (100 g carb, 700 kcal in 16 fl 
Protocol GLY-200-02 AM02V01
06 October 2022
Confidential        42
requirements, where applicable, and the IRB/IEC or study center.
The medical record must include a statement that written informed consent was obtained before 
the participant was enrolled in the study and th e date the written consent was obtained. The 
authorized person obtaining the informed consent must also sign the ICF.
Participants must be re-consented to the most current version of the ICF(s) during their 
participation in the study.
A copy of the ICF(s) must be provided to the participant. 
DATA PROTECTION
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will  contain the identifier only; participant names or 
any information which would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study-related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant who will be required to give consent for their data to be used as 
described in the informed consent.
The participant must be informed that his/her medical records may be examined by [CONTACT_19491], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
COMMITTEES STRUCTURE 
Not applicable.
SAFETY OVERSIGHT
Clinical safety oversight will be performed  by [CONTACT_729900]. In addition, on-site review of all data including safetydata will be conducted routinel y by [CONTACT_502558] /clin ical research associates.
DISSEMINATION OF CLINICAL STUDY DATA
This study will be posted on the US Nati onal Institutes of Health‚Äôs website 
www.clinicaltrials.gov .
DATA QUALITY ASSURANCE
As defined by [CONTACT_16968], the CRF is a prin ted, optical, or electronic document designed to 
record all protocol-required information to be reported to the Sponsor on each study subject.
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically  (e.g., laboratory data). The Investigator is 
responsible for verifying that data entries are accu rate and correct by [CONTACT_112247].
Protocol GLY-200-[ADDRESS_996938]‚Äôs source documents and on the eCRFs, unless otherwise noted. All data 
on these eCRFs should be recorded completely and promptly. A copy of the completed eCRFs 
for each subject will be retained by [CONTACT_118250].
The Investigator must maintain adequate an d accurate source documents upon which eCRFs for 
each subject are based. They are to be separate and distinct from eCRFs, except for cases in 
which the Sponsor has predetermined that direct da ta entry into specified pages of the subject‚Äôs 
eCRF is appropriate.
Study monitors will perform ongoing source data veri fication to confirm that data entered into 
the eCRF by [CONTACT_407421], complete, and verifiable from source 
documents; that the safety and rights of particip ants are being protected; and that the study is 
being conducted in accordance with the curren tly approved protocol and any other study 
agreements, ICH GCP, and all applicable regulatory requirements.
STUDY RECORDS RETENTION 
During this study, the Investigator is required to prepare and maintain ade quate and accurate case 
histories designed to record all observations and ot her data pertinent to th e investigation on each 
individual treated with the IP or entered as a control in the investigation.Records and documents, including signed ICFs, pert aining to the conduct of this study must be 
retained by [CONTACT_729901] (1) applicable regulations and 
guidelines or institution procedures or (2) for the period specified by [CONTACT_1034], whichever is 
longer. The Investigator must contact [CONTACT_729902]. No records may be destroyed during th e retention period without the written approval 
of the Sponsor.
The Sponsor will notify the Investigator when the study records are no longer needed.In the event the Investigator withdraws from the study (e.g., relocation, retirement), the records 
shall be transferred to a mutually agreed-upon de signee (e.g., another Investigator). Notice of 
such transfer will be given in writing to the Sponsor.
The Sponsor will maintain correspondence with the Investigator after study closeout to ensure 
that study documentation is retained for the appropriate amount of time. 
Protocol GLY-200-02 AM02V01
06 October 2022
Confidential        44
QUALITY ASSURANCE AND QUALITY CONTROL
This study will be organized, performed, and repor ted in compliance with the protocol, SOPs, 
site/Investigator training, and applicable regula tions and guidelines. Clinical Investigator sites
will be trained at the Investigator  Meeting(s) and/or at on-site visits. All aspects of the study will 
be monitored carefully by [CONTACT_1034]‚Äôs designees with respect to current GCP and SOPs for 
compliance with applicable governme nt regulations. It is the responsibility of the Investigator to 
provide all study records, including CRFs and source documents, among other records, for review and inspection by [CONTACT_24653],  representatives of the Sponsor, and regulatory 
authorities, as needed.
Clinical monitoring will be performed per the Clinical Monitoring Plan. Clinical 
monitors/clinical research associates will peri odically evaluate the progress of the study, 
including the verification of appropriate consent form procedures and the verification of the 
accuracy and completeness of eCRFs. Clinical monitors/clinical research associates will also 
ensure that all protocol requirements, applicable US FDA regulations, other regulatory requirements, and the Investigator‚Äôs obligations are being fulfilled.
PROTOCOL DEVIATIONS
A protocol deviation is any nonc ompliance with the clinical trial protocol or ICH GCP. The 
noncompliance may be either on the part of the pa rticipant, the Investigator, or the study site 
staff. 
The Investigator and study staff will apply due diligence to avoid protocol deviations. If protocol 
deviations do occur, the Investigator or study staff must report them to the local IRB/IEC per 
their policies.
PREMATURE TERMINATION OR STUDY SUSPENSION
The Sponsor reserves the right to prematurely terminate the study or specific groups within the 
study at any time for administrative, safety, or treatment-related benefit-risk reasons. Written 
notification documenting the reason for study suspen sion or termination will be provided to the 
Investigator and regulatory authorities as appropriate. If the study is prematurely terminated or 
suspended, the Investigator will promptly inform the IRB and will provide the reason(s) for the termination or suspension.
PUBLICATION POLICY
The results of this study may be published or presente d at scientific meetings. If this is foreseen, 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments.
The Sponsor will comply with the requirements for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating Investigator [INVESTIGATOR_12992].
Authorship will be determined by [CONTACT_729903]-200-02 AM02V01
06 October 2022
Confidential        45
Medical Journal Editors authorship requirements.  
FUTURE USE OF STORED SPECIMENS AND DATA
Data and biospecimens collected in this study may be useful for other research studies. 
Samples (blood, urine, and fecal) will be stored fo r future metabolite analysis and may be used to 
assess additional PK and PD markers of GLY-200.
Protocol GLY-200-[ADDRESS_996939] in this study:
xHyperglycemia with evidence of diabetic ketoacidosis (DKA) or impending DKA : A blood glucose 
value > 300 mg/dL with symptoms of DKA (e.g., nausea, dizziness, abdominal pain, lethargy) and 
capi[INVESTIGATOR_729892] > 1.5 mmol/L or urine ketone positivity
xClinically significant hypoglycemia : A blood glucose measurement of <54 mg/dL (<3.0 mmol/L) that 
may or may not have immediate symptoms depending on the level of hypoglycemia unawareness
DEFINITION OF SAE
An SAE is defined as any serious adverse event that, at any dose:
1. Results in death
2. Is life-threatening
xThe term ‚Äòlife-threatening‚Äô in the definition of ‚Äòserious‚Äô refers to an event in which the subject was at 
risk of death at the time of the event. It does not refer to an event, which hypothetically might have 
caused death, if it were more severe.
3. Requires inpatient hospi[INVESTIGATOR_729893], hospi[INVESTIGATOR_12994] (usually involving at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have 
been appropriate in the physician‚Äôs office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether ‚Äúhospi[INVESTIGATOR_059]‚Äù occurred or was necessary, the AE should be considered serious.
xHospi[INVESTIGATOR_5187] a pre-existing condition that did not worsen from baseline is not considered an AE.
4. Results in persistent or significant disability/incapacity
xThe term disability means a substantial disruption of a person‚Äôs ability to conduct normal life functions.
xThis definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.
5. Is a congenital anomaly/birth defect
6. Is an important medical event, defined as an event that does not fit one of the other outcomes, but may 
jeopardize the subject and may require medical or surgical intervention (treatment) to prevent one of the other outcomes
xExamples of such events include intensive treatment for allergic bronchospasm (a serious problem with 
breathing) requiring treatment in an emergency room, serious blood dyscrasias (blood disorders), seizure/convulsion that does not result in hospi[INVESTIGATOR_729894].
Protocol GLY-200-02 AM02V01 
06 October 2022 
Confidential              48 
DEFINITION OF UNANTICIPATED PROBLEMS (UP) 
UP Definition
xAn unanticipated problem is defined as, in general, any incident, experience, or outcome that meets all of 
the following criteria: 
oUnexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol-related documents, such as the IRB-approved research protocol and informed consent document; and (b) the characteristics of the subject population being studied; 
oRelated or possibly related to participation in the research (‚Äúpossibly related‚Äù means there is areasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and 
oSuggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.
  
RECORDING AND FOLLOW-UP OF AE AND/OR SAE
AE and SAE Recording
xSerious Adverse Events (SAEs) should be reported to the Sponsor and/or CRO within 24 hours from 
the discovery of the event. 
xWhen an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g., 
hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.
xThe Investigator will then record all relevant AE/SAE information.
xThe Investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Severity
The investigator will make an assessment of severity for each AE and SAE reported during the study and assign it 
to 1 of the following categories: 
xMild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort and not interfering 
with everyday activities.
xModerate: An event that causes sufficient discomfort to interfere with normal everyday activities.
xSevere: An event that prevents normal everyday activities. An AE that is assessed as severe should not be 
confused with an SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and 
SAEs can be assessed as severe.
An event is defined as ‚Äòserious‚Äô when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Relationship to Study Agent
The relationship of the study treatment to an AE will be determined by [CONTACT_233913]:  
1. Not Related 
The AE is not related if (1) administration of the study medication has not occurred or (2) the occurrence of 
the AE is not reasonabl y related in time or(3) the AE is considered related to another event, medical 
Protocol GLY-200-[ADDRESS_996940] not associated with the study medication (such as disease progression, environmental 
factors, unrelated trauma, etc.) 
2.  Unlikely Related
The AE is unlikely related if (1) the AE is unlikely related in time or(2) the AE is considered unlikely to be 
related to use of the study medication (i.e., there are no facts [evidence] or arguments to suggest a causal 
relationship), orthe AE is considered possibly related to another event, medical condition or product not 
associated with the study medication. 
3.  Possibly Related
The AE is possibly related if (1) the study medication and AE are considered reasonably related in time and
(2) the AE could equally be explained by [CONTACT_729904]. 
4.  Probably Related
The AE is probably related if (1) the study medication and AE are considered reasonably related in time and 
(2) the study medication is more likely than other causes to be responsible for the AE or is the most likely cause of the AE.
xThe Investigator will use clinical judgment to determine the relationship.
xAlternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as well as the temporal relationship of the event to study intervention administration will be considered and investigated.
xThere may be situations in which an SAE has occurred and the Investigator has minimal information to include in the initial report (refer to Section 10.2.5 ). However, it is very important that the Investigator 
always make an assessment of causality for every event before the initial transmission of the SAE data (refer to Section 10.2.5 ). 
xThe Investigator may change his/her opi[INVESTIGATOR_9242]-up information and send an SAE follow-up report with the updated causality assessment.
xThe causality assessment is one of the criteria used when determining regulatory reporting requirements.
Assessment of Expectedness
xThe Sponsor will be responsible for determining whether an AE/SAE is expected or unexpected.
xAn AE/SAE will be considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk information previously described for the study agent in the IB or is not listed in the IB at the specificity or severity that has been observed. 
REPORTING OF SAES
SAE Reporting to Sponsor and IRB
xAny AE that meets any criterion for an SAE requires the completion of an SAE Report Form in addition to being recorded on the AE page/screen of the eCRF. 
xAll SAEs must be reported by [CONTACT_729905] 24 hours of the 
Investigator‚Äôs knowledge of the event. 
oSponsor Drug Safety Contact [CONTACT_7171]: [EMAIL_13909]   
oProSciento Safety Team Email: [EMAIL_13910]
xThe Investigator is required to ensure that the data on these forms is accurate and consistent. This 
requirement applies to all SAEs (regardless of relationship to IP) that occur during the study (from the time the participant si
gns informed consent until post-treatment follow up visit, or an y SAE made known to the 
Protocol GLY-200-02 AM02V01
06 October 2022
Confidential        50
SAE Reporting to Sponsor and IRB
Investigator at any time thereafter that are suspected of being related to IP). Serious adverse events 
occurring prior to treatment (after signing the ICF) will be captured.
xThe SAE report should provide a detailed description of the SAE and include a concise summary of hospi[INVESTIGATOR_27598]. If a participant died and an autopsy has been performed, copi[INVESTIGATOR_729895]. Any follow-up data should be detailed in a subsequent SAE Report Form, or approved equivalent form, and sent to Sponsor Drug Safety or its designee. 
xWhere required by [CONTACT_19666], the Investigator is responsible for informing the IRB/EC of the SAE and providing them with all relevant initial and follow-up information about the event. The Investigator must keep copi[INVESTIGATOR_729896]/EC.
xDetails will be provided in the Safety Management Plan (SMP).
xThere may be instances when copi[INVESTIGATOR_29482]. In this case, all subject identifiers, with the exception of the subject number, will be redacted on the copi[INVESTIGATOR_321293].
REPORTING OF UPS
Unanticipated Problem Reporting
xIncidents or events that meet the criteria for unanticipated problem require the creation and completion of an UP report. It is the site Investigator‚Äôs responsibility to report UPs to their IRB and to the Sponsor. The 
UP report will include the following information: 
oProtocol identifying information: protocol title and number, PI‚Äôs name, and the IRB project number; 
oA detailed description of the event, incident, experience, or outcome; 
oAn explanation of the basis for determining that the event, incident, experience, or outcome represents an UP; and 
oA description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP. 
xTo satisfy the requirement for prompt reporting, UPs will be reported using the following timeline: 
oUPs that are SAEs will be reported to the IRB and to the Sponsor within 24 hours of the Investigator becoming aware of the event. 
oAny other UP will be reported to the IRB and to the Sponsor within the IRB-required reporting timeframe. 
oAll UPs should be reported to approp riate institutional officials (as required by [CONTACT_17347]‚Äôs 
written reporting procedures) and IRB within the timeframe specified by [CONTACT_729906].
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              53 
Abbreviations: RBC = red blood cell; WBC = white blood cell; PT = prothrombin time; INR = international 
normalized ratio; aPTT = activated partial prothrombin time; HIV = Human Immunodeficiency Virus; HBsAg = 
Hepatitis B surface antigen; LDH = lactate dehydrogenase; ALP = alkaline phosphatase; ALT = alanine 
aminotransferase; AST = aspartate aminotransferase; GGT = gamma-glutamyl transferase; HDL = high-density 
lipoprotein; LDL = low-density lipoprotein; TIBC = total iron binding capacity; HCV = hepatitis C virus; hCG = 
human chorionic gonadotropin; CRP = C-reactive protein. 
 
  
 
 Protocol GLY-200-[ADDRESS_996941]  
HR heart rate 
IB Investigator's Brochure 
IBD inflammatory bowel disease 
IBS irritable bowel syndrome 
ICF informed consent form 
ICH International Council for Harmonisation  
IP investigational product 
IRB Institutional Review Board 
IV intravenous 
LDL low-density lipoprotein  
MAD multiple ascending dose 
MedDRA Medical Dictionary for Regulatory Activities  
MMTT mixed meal tolerance test 
NSAIDs nonsteroidal anti-inflammatory drugs 
PD pharmacodynamic(s) 
PK pharmacokinetic(s) 
PT preferred term 
PYY peptide YY 
RR respi[INVESTIGATOR_729897]-en-Y gastric by[CONTACT_729907](s) serious adverse event(s) 
SAP statistical analysis plan 
SD standard deviation  
SEM standard error of the mean 
SoA Schedule of Activities  
SOC system organ class 
SOP standard operating procedure 
T2D type 2 diabetes 
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              56 
Abbreviation Term 
TEAE(s) treatment-emergent adverse event(s) 
TID three times a day 
ULN upper limit of normal 
UP Unanticipated Problem 
VAS visual analog scale 
wt. weight 
 
 
  
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              59 
Change Section(s) Affected Rationale 
Day 14.‚Äù 
Section 6.1.2 was updated: ‚ÄúEach 
subject will be randomly assigned to a 
group at Day -1 or  Day 1.‚Äù Section 6.1.2 Update was made to allow for randomization on Day -1.  
Tetrahydrocannabinol was removed from the ‚ÄúDrugs of abuse‚Äù screen. Section 8.2.[ADDRESS_996942] as it is not an exclusionary drug.  
‚ÄúClinically significant hyperglycemia‚Äù and ‚Äúclinically significant 
hypoglycemia‚Äù (and definitions) were added to as AEs of special interest.  Section 8.3.7 and 
Section 10.2.1 Additions were made per FDA recommendation. 
‚ÄúFasting Lipi[INVESTIGATOR_805]‚Äù was removed from the ‚ÄúDay 1 predose and Day 14 only‚Äù clinical laboratory assessments. Section 10.[ADDRESS_996943] chemistry lab is sufficient.  
 
Amendment 01 Version 01 Summary of Changes 
Purpose:   The primary purpose of this amendment is to address FDA comments received in 
response to the protocol submission as part of the original IND. Additional edits are 
also made to refine and clarify the study procedures. 
Summary of Changes 
Change Section(s) Affected Rationale 
Added amendment version/date and 
Summary of Changes Throughout and 
Section [ADDRESS_996944] protocol Amendment 01 
Sponsor Signature [CONTACT_729908]. Sponsor Signature 
[CONTACT_729909], Section 
1.3.1, Section 3, and 
Section 8.4 To refine exploratory PD tests 
Inclusion criterion 1c was revised: ‚ÄúHbA1c ¬ï 7 6.5  DQG¬î 9.6 8.5% at 
screening‚Äù Synopsis, Section 5.1 Per FDA recommendation 
Inclusion criterion 1d was added:     ‚Äúd. completed at least 12 days of 
metformin washout without meeting Synopsis, Section 5.1 To clarify that subjects meeting criteria 
for rescue during the washout period 
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              60 
Change Section(s) Affected Rationale 
rescue criteria prior to dosing‚Äù will not be randomized 
Inclusion criterion 3 was revised: BMI 
¬ï  DQG ¬î at screening  Synopsis, Section 5.1 To clarify timing of inclusion/exclusion criteria assessment 
Exclusion criterion 8 was revised: Fasting blood glucose > 210 190 
mg/dL at screening; can be reassessed 
once during the screening period Synopsis, Section 5.2 Per FDA recommendation 
‚ÄúUrine Dipstick (ketones)‚Äù row was removed from the SoA. Section 1.3 Ketones are assessed as part of clinical laboratory urinalysis. 
‚ÄúFSH Test‚Äù row was added to the SoA.  Section 1.[ADDRESS_996945] FSH testing performed on postmenopausal women at screening 
The following was added to the SoA: ‚ÄúNote: Prescreening laboratory values can be used to determine subject 
eligibility if they were collected within 
the screening window.‚Äù Section 1.3 To clarify screening procedures 
Footnote 9 was updated in the SoA: ‚ÄúECGs will be taken after at least 10 5 
minutes resting quietly‚Ä¶‚Äù Section 1.3 For consistency with Section 8.2.6 Electrocardiograms 
The following was added to SoA footnote 15: ‚ÄúApproximate weights of 
fecal collections should be recorded by 
[CONTACT_6624].‚Äù Section 1.3 To refine study procedures 
Footnote 18 was updated in the SoA: ‚ÄúRecording of water and fluids in and 
output (urine volume out) over 24 
hours daily during confinement.‚Äù   Section 1.3 To clarify that fluid balance is only being performed on a subset of inpatient days as noted in the SoA 
The following was added to the protocol: ‚ÄúFractionated bile acids will be analyzed in a subset of 
subjects/doses based on initial total 
bile acid data.‚Äù  Section 1.3.1 and 
Section 8.4 To refine exploratory PD analysis testing strategy 
The following was added to Section 6.8.2 Rescue Medicine: ‚ÄúFasting blood glucose will be measured by [CONTACT_483625] a home glucose meter Section 6.8.2 To clarify that subjects meeting criteria 
for rescue during the washout period will not be randomized 
 
 Protocol GLY-200-02 AM02V01 
06 October 2022 
 
Confidential              61 
Change Section(s) Affected Rationale 
daily from Day -[ADDRESS_996946] will not be randomized.‚Äù 
Section 8.2.6 Electrocardiograms was 
edited: ‚ÄúDay [ADDRESS_996947] dose ECGs will be single 
readings.‚Äù Section 8.2.6 To enhance accuracy; Day [ADDRESS_996948] is part of the site‚Äôs prescreening process.  
Section 8.4 was reorganized, and calprotectin (fecal analysis) and calcium (urine analysis) were deleted.  Section 8.4 To clarify exploratory PD vs PK markers and to delete assays that were included in error 
Corrected section references in Section 10.2.4 Recording and Follow-up of AE and/or SAE Section 10.2.4 Administrative edit; section references in Assessment of Relationship to Study Agent were incorrect 
Added sponsor drug safety contact [CONTACT_3031]. Section 10.2.5 Previously omitted in error 
Appendix 4: Clinical Laboratory Assessments was edited: 
x Clarification was made to refer to the SoA for timepoints 
x Full iron panel was defined 
x Timing of ‚ÄúOther Serum & Plasma tests‚Äù was clarified 
x Abbreviations were updated for completeness. Section 10.4 Edits were made to clarify clinical laboratory assessments 
 